Glycotest IP strategy is to enable multiple layers of protection for key liver disease tests through multiple patent families prosecuted in commercially important jurisdictions—individual biomarkers; assay technology; panels and algorithms
HCC Panel patent application (PCT/US2017/018040 and Taiwan 106106107)
- Panels and algorithms, including the HCC Panel
- Protection to 2037, including in China
PCT/US2010/044307
- Engineered lectins and methods for fucosylated biomarker assays
- Issued European (2462240) and Chinese (ZL201080044720.8) patents
- Protection to 2030, including in China
PCT/US2006/017478
- Methods for diagnosing liver disease using fucosylated biomarkers
- Issued US (7,776,550; 8,183,000; 10,082,512; 10,823,740), European (3056905; 3578985), Australian (2006244398; 2012247075; 2015275300), Japanese (5964769; 6184935; 6553142), Canadian (2607285), and Hong Kong (HK1228005) patents and allowed Canadian patent
- Protection to 2026
US2009/0253180
- Methods for diagnosing liver disease using fucosylated LRAGG
- Issued US patents (9,110,078; 10,180,436)
- Protection to 2028
Trade Secrets
- Fucosylated biomarker assay manufacturing technology
- Fucosylated biomarker assay methods